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Presently  the  development  of  new  therapies  for  hepatitis  C virus  (HCV)  is rapidly  moving  forward.  Almost
every week  new  data  appear  on  how  direct  acting  antivirals  (DAAs)  succeed  or  fail  in clinical  trials.  Despite
the  potency  of many  of  the  DAA  combinations,  the effect  exerted  by  ribavirin  (RBV)  is  still  needed  for  an
effective  therapy  in  many  new  DAA  combinations.  Due  to  the  strong  antiviral  effect  of  DAAs,  it is  likely
that  a  major  complementary  therapeutic  effect  exerted  by  RBV  is  immune  modulation  resulting  in an
increased  barrier  to  development  of  resistance.  For  HCV  genotype  1a  infections  elimination  of  pegylatedNA vaccine
lectroporation
 cell
interferon,  is not  possible  in  many  DAA  combinations  without  jeopardizing  the  results.  The  host  immune
response  is  thus  likely  to play a key  role  even  during  DAA-based  therapies.  Hence,  T  cells  may  recognize
and eliminate  viral  variants  with  resistance  to  the  DAAs.  We  herein  show  several  examples  where  this
may  be the  case,  supporting  the  rationale  of including  the  host  response  also  in  the  new  therapeutic
regimens.  This  review  will  describe  the  potential  beneﬁts  of  combining  various  DAAs  with  means  to
activate  the  speciﬁc  immune  response  against  HCV.© 2013 Elsevier Ltd. All rights reserved.
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ttp://dx.doi.org/10.1016/j.drup.2013.06.0011. IntroductionThe development of therapies for chronic infections caused by
the hepatitis C virus (HCV) has exploded in the past ﬁve years
with the introduction of direct acting antiviral (DAA) compounds
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Hofmann and Zeuzem, 2011; Welsch et al., 2012). Pegylated inter-
eron alpha 2a, or 2b (IFN) and ribavirin (RBV) is presently still
sed as a backbone when combined with the 1st generations pro-
ease inhibitors (PIs) against HCV (McHutchison et al., 2009). The
fﬁciency of the combination is dependent on the host IL-28B geno-
ype (CC, CT, or TT), the viral genotype (gt) 1–6, and the viral load
Ge et al., 2009). The IL-28B genotype also predicts the chance to
chieve spontaneous resolution of an acute HCV infection (Thomas
t al., 2009). By using baseline factors a prediction of sustained viral
esponse (SVR) can be done with moderate accuracy. In addition,
he kinetics of the early viral kinetics during therapy has been found
ery useful for the prediction of SVR and has generated stopping
ules during therapy when a low probability for eventual ﬁnal cure
s at hand (Sherman et al., 2011). This reduces overtreatment and
nnecessary treatment and reduces the cost and adverse events in
atients who will have a low chance to achieve SVR and hence be
aken off therapy.
IFN/RBV treatment does not cause emergence of viral resistance
nd the mechanisms for non-response to IFN/RBV is poorly under-
tood. Viral strains which do not respond to IFN therapy with an
t least 2 log decline during the initial 12 weeks treatment could
e deﬁned as resistant to IFN/RBV and are deﬁned as null respon-
ers (Wedemeyer et al., 2012a). No speciﬁc mutations have been
ssociated with such resistance. However, identiﬁcation of an inter-
eron sensitivity-determining region (ISDR) has been published in
apanese patients (Enomoto et al., 1996). With respect to RBV no
peciﬁc viral genotype or phenotype resistance has been identiﬁed.
This strongly contrasts to what is seen with the direct acting
ntivirals (DAAs; Fig. 1), where resistance mutations are readily
etected in the target protein, which explain the lack of efﬁ-
acy once they occur (Welsch et al., 2012). Identiﬁcation of viral
esistance mutations, hence, can be expected to play a role dur-
ng monitoring of treatment with new DAA-based combination
herapies. New treatment strategies with combination of several
AA compounds targeting different regions of HCV will be used
o overcome emergence of resistance if such combinations will
e sufﬁcient or if addition of immune modulating therapies will
e needed in difﬁcult to treat patients remains to be explored
Figs. 2 and 3).
.1. The mechanisms of action of IFN and RBV
After having acknowledged that the combination of IFN and
BV can cure around 50% of the patients with chronic genotype
 (gt1) HCV infection and some 80% of genotype non-1 infec-
ions, the question arises how these drugs act on the infected cell.
ith respect to IFN, it is well known that it binds to the IFN/
eceptor (IFNAR), which is composed of the two  subunits IFNAR1
nd IFNAR2, constitutively expressed on the surface of many cells
ncluding hepatocytes. The binding of IFN to its receptor results
n the activation of the Janus kinases Jak1 and Tyk2, which phos-
horylate signal transducer and activator of transcription (STAT) 1
ig. 1. Description of the functions of the non-structural HCV proteins and how the
ifferent classes of DAAs interacts with these.Updates 16 (2013) 60– 67 61
and 2. STAT1 and 2 form a complex with the IFN-regulatory factor
9 (IRF9), which binds to IFN-stimulated response elements (ISRE)
on DNA leading to the expression of several hundred genes named
IFN-stimulated genes (ISGs). These ISGs have a variety of antivi-
ral, antiproliferative and immunomodulatory effects. Some of them
such as the protein kinase R (PKR) or the 2′–5′oligoadenylate syn-
thetase (OAS) directly inhibit viral transcription and translation
and, thus, reduce virus replication, and others act by strengthen-
ing the antiviral immune response. Hence, IFN is known to be
involved in the induction of T cell proliferation, the activation of
NK cells, the maturation of dendritic cells and the prevention of T
cell apoptosis (Pitha and Kunzi, 2007).
Successful IFN treatment is characterized by two phases
(Neumann et al., 1998). In the ﬁrst phase, a rapid decline of the
viral load is believed to be caused by a direct antiviral effect exerted
by IFN (Neumann et al., 1998). The antiviral effect is mediated
by ISGs such as the PKR or the 2′–5′ OAS, which reduce the viral
replication by directly inhibiting viral transcription and transla-
tion. The second, and slower viral decline phase is thought to be
immune mediated by the IFN/RBV stimulation of innate and adap-
tive immune system. IFN is e.g. known to be involved in the
induction of T cell proliferation and cytotoxicity (Le Bon et al.,
2006a,b), the activation of NK cells (Trinchieri and Santoli, 1978),
the maturation of dendritic cells (Le Bon et al., 2001) and the aug-
mentation of B cell responses (Le Bon et al., 2001; Badr et al., 2010).
RBV on the other hand has a much less well characterized
effect on the infected cell. Several direct or indirect mechanisms
have been proposed. RBV is well known to deplete the cell of the
guanosine tri-phosphate (GTP) necessary for viral RNA synthesis
by blocking the enzyme inosine-5′-monophosphate dehydroge-
nase (IMPDH) (Malinoski and Stollar, 1981). Furthermore, RBV has
been proposed to act as an inhibitor of the RNA-dependent RNA
polymerase (Maag et al., 2001), and as a mutagen causing an error
catastrophe (Crotty et al., 2000). The high concentrations needed for
RBV to act as a direct antiviral agent causes major adverse events
and cannot be used in practice, and are difﬁcult to reach in vivo
(Zoulim et al., 1998). Hence, the effect of ribavirin during HCV ther-
apy is likely to be immune modulatory e.g. by altering the Th1/Th2
balance towards an antiviral Th1 response (Hultgren et al., 1998;
Ning et al., 1998), or by inducing the expression of ISGs (Liu et al.,
2007; Zhang et al., 2003). Even today when using new highly potent
DAA drugs RBV seems to be needed as a complement to increase
the efﬁcacy via a presumed immune modulatory effect which is not
provided by the current DAAs.
It is important to note that the most refractory patients to
IFN/RBV combination therapy are those with ISG already switched
on (Sarasin-Filipowicz et al., 2008). The continuous activation of
ISGs by intracellular HCV RNA in these patients is not sufﬁcient to
clear the virus but results in an upregulation of negative regulators
in the Jak-STAT pathway such as protein inhibitor of activated STAT
(PIAS) 1 and suppressor of cytokine signalling (SOCS) 3 causing a
decrease in the sensitivity to IFN. Patients lacking an ongoing IFN
response before therapy, who do not have upregulated ISGs, will
have a strong ISG induction and activation of an intrahepatic IFN
necessary for the treatment to be effective.
An important ﬁnding linking the host immune response to treat-
ment outcome was the identiﬁcation of the IL-28B (IFN3) single
nucleotide polymorphisms (SNPs) (Ge et al., 2009; Suppiah et al.,
2009; Tanaka et al., 2009). It was shown that patients with geno-
type (rs12979860 CC or rs8099917 TT) had much higher SVR rates
than patients lacking this polymorphism. Interestingly, hepatic ISG
expression before treatment was  initiated was  found to be sig-
niﬁcantly lower in patients with the favourable IL28B genotype
(Honda et al., 2010). IFN/RBV combination therapy in these patients
resulted in a strong ISG induction and a better treatment response
with higher SVR rates.
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As IFN,  IFN beta, and IFN activates the Jak-STAT pathway
esulting in the expression of ISGs through different receptors. The
FN receptor is expressed only in speciﬁc cell types such as hepa-
ocytes, epithelial cells, bone marrow cell lines, and plasmacytoid
endritic cells (Sommereyns et al., 2008). IFN is characterized by
 potent antiviral activity and less pronounced side effects since it
oes not bind to bone marrow cell lines. Due to this it is currently
ested in clinical phase 3 trials (Muir et al., 2010; Zeuzem et al.,
011).
.2. The mechanisms of action of the major classes of DAAs
Before 2011 the only available treatment for HCV, was consist-
ng of pegylated IFN and RBV. Now two compounds from the ﬁrst
eneration protease inhibitors, Boceprevir (Merck) and Telapre-
ir (Janssen, Vertex Pharmaceuticals), has been approved for use
n man. More effective DAAs from different classes such as poly-
erase inhibitors, NS5A inhibitors, and second generations PIs are
nder fast development and expected to be available within the
ext few years, which will improve treatment substantially (Fig. 1).
lready 2003 the non-structural (NS)3/4A protease inhibitor (PI)
ILN2061 was tested during two days and shown to effectively
educe the HCV replication (Lamarre et al., 2003). The develop-
ent of BILN2061, however, was terminated due to toxicity. This
as the start of the DAA era for treatment of HCV. Presently we
ave two approved NS3 PIs, Boceprevir and Telaprevir, both less
otent than BILN2061 but with less pronounced but still signif-
cant adverse events (Zeuzem et al., 2011; Poordad et al., 2011).
hen either of these two PIs is added to the IFN/RBV combination
herapy the SVR rate increases from 45% to 75% in patients infected
y HCV gt1 strains (Zeuzem et al., 2011; Poordad et al., 2011). Even
hough the response rates have been improved, and for a majority of
atients have allowed shorter treatment duration, the triple com-
ination is complicated and associated with cumbersome adverse
vents, and a substantial pill burden. Moreover, the currently
pproved 1st generation PIs works poorly in non-gt1 infected
atients.The second generation PIs with TMC435 (Simeprevir, Medi-
ir, Janssen) and Asunaprevir (BMS) ﬁrst in line are more potent
nd have less pronounced side effects and can be taken once
aily. TMC435 has been shown to reduce HCV RNA levels by
Fig. 2. An example on how the HCV-speciﬁc T cell respUpdates 16 (2013) 60– 67
2–4 log(10) IU/mL and is effective for genotypes 1, 2, 4, 5 and 6,
but not for gt 3. It is also better tolerated than the ﬁrst genera-
tions PIs (Moreno et al., 2012). As for Asunaprevir, several studies
have demonstrated rapid and substantial decrease in HCV RNA lev-
els in patients with gt1 chronic HCV infection in particularly gt
1b infections (Lok et al., 2012; Pasquinelli et al., 2012). The major
mechanism of action for the protease inhibitors is to sterically block
cleavage of the HCV polyprotein. The protease inhibitors are gener-
ally peptidomimetics simply resembling the natural substrate for
the NS3/4A protease. A further additive effect is the inhibitory effect
on the cleavage of the host proteins MAVS and TRIF, both signal
transducers in the cellular interferon response to the presence of
double stranded RNA (Gale and Foy, 2005), and the TC-PTP protein
responsible for activation of transcription factors needed for HCV
replication (Brenndorfer and Sallberg, 2012).
While most focus has been directed against the serine protease
active site of NS3, new classes of DAAs are under development and
evaluated in clinical trials (Figs. 1–3). There are several compounds
targeting the NS5A protein. The NS5A inhibitors bind to the NS5A
protein with a function still not fully understood. NS5A has been
suggested to be involved in the formation of the membraneous
web  whereby a blocking of this function would disturb the HCV
replication. Daclatasvir (BMS-790052, Bristol-Myers Squibb; Fig. 1)
is a promising NS5A inhibitor with a high antiviral potency but a
low resistance barrier without a backbone of IFN/RBV treatment
(Gao et al., 2010; Nettles et al., 2011; Pol et al., 2012). It is highly
effective when combined with the NS5B nucleoside analogue GS-
7977 (Sofosbuvir, Gilead). This combination has been suggested
to result in a high proportion of cure rates in early clinical trials.
Sofosbuvir has shown very promising results in combination with
IFN/RBV for gt1 or with only RBV for gts 2 and 3 (Gane et al., 2013;
Jacobson et al., 2013; Lawitz et al., 2013). Another promising NS5A
inhibitor is GS-5885 (Gilead) that is currently evaluated in a sev-
eral different DAA containing regimens (NS3, NS5A, NS5B) with
or without RBV (http://www.natap.org/2012/EASL/EASL 32.htm).
Also Abbot has several DAAs in development, a ritonavir boosted PI
(ABT-450/r), a NS5A inhibitor (ABT-267), and a non-nucleoside ana-
logue (ABT-333) which in combination with or without RBV have
shown potent antiviral activity and SVR rates over 90% also with
treatments as short as 8–12 weeks, as recently reported at AASLD
in Boston 2012 as a late breaker poster number 1.
onse can recognize DAA resistant viral variants.
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Nucleoside analogues are a very promising family of DAAs that
re explored as the NS5B inhibitors. The NS5B RNA-dependent RNA
olymerase (RdRp) is responsible for the synthesis of new negative
nd positive HCV RNA strands. The two classes of drugs are nucleo-
ide (NUC) and non-nucleoside (non-NUC) inhibitors. The NUCs
re basically chain terminators that when incorporated into the
ewly synthesized RNA chain by NS5B, stops chain elongation due
o steric hindrance at the catalytic site. The non-nucleoside (non-
UC) inhibitors interfere with NS5B at sites outside the catalytic
ite and act by altering the conformation of the NS5B molecule,
hereby these can have additive effect in combination with the
UCs. The presently most promising NUC is the GS-7977 (Sofosbu-
ir, Gilead) as described above. It is reported to be safe, and to have
 high antiviral activity combined with a high resistance barrier. In
ombination with a NS5A inhibitor it seems to achieve high SVR
ates in all genotypes in IFN free regimens (Sulkowsky LB 2 AASDL
012 in Boston).
Non-nucleoside analogues are generally less potent than
ucleoside analogues and have a much lower resistance barrier.
his means that they need to be used in combinations with more
han one other DAA drug to avoid emergence of resistance. One
uch example (ABT-333, Abbot) when combined with the ritonavir
oosted NS3/4A PI ABT-450/r and the NS5a inhibitor ABT-247+/−
BV achieved > 90% SVR with only 8–12 weeks of treatment in
reatment naïve subjects infected with gt 1 as described earlier. In
igs. 2 and 3 the appearance of DAA-induced resistance mutations
ithin known CTL epitopes have been shown.
. The mechanism(s) of immune modulation
.1. Vaccines
One way to treat a HCV infection is to utilize vaccines that
im at inducing strong and multifunctional CD4+ and CD8+ T cell
esponses. This type of immune response is found in patients that
pontaneously clear their HCV infection but is lacking in patients
ith established chronic infection (Diepolder et al., 1995; Penna
t al., 2007). The need for a therapeutic vaccine can be questioned
hen the introduction of highly effective DAA drugs with SVR
ig. 3. Example of known resistance mutations to DAAs located within known CTL epitop
re  shown in red.Updates 16 (2013) 60– 67 63
rates approaching 90% have come on the market. Difﬁcult to treat
patients groups, however, who needs alternative additive treat-
ments will still exists. For such groups, therapeutic vaccines may  be
an option, preferably used in combination with DAAs, the old SOC
(IFN/RBV) or together with other immune modulating agents. The
mechanism by which immune modulation is achieved with ther-
apeutic vaccines is thought to be a successful reactivation of the
dysfunctional HCV-speciﬁc T cell response present in individuals
with a chronic HCV infection. This in turn will improve the chance
for SVR with any subsequent or parallel DAA treatment regimen. An
immune reactivation can be accomplished by using different vac-
cine compositions. The following vaccine combinations have been
used in pre-clinical and clinical studies: recombinant protein/s,
peptides, virosome-peptide formulations, DNA, DNA-recombinant
proteins, adenovirus vectors, MVA  vectors, iscomatrix, yeast pro-
teins, prime-boost approaches using DNA–protein, MVA–Adeno,
and Adeno–Adeno. In addition, several of these therapeutic vac-
cines have been administered to HCV infected individuals. Patients
have subsequently been treated with pegylated IFN and RBV. In
the future therapeutic vaccines can also be combined with DAA
drugs, which will hopefully improve treatment outcome further,
particularly in difﬁcult to treat patients.
Mutations within and/or outside immunological epitopes
towards which the vaccines are directed may appear after thera-
peutical vaccinations and new resistant viral strains may  emerge.
If this happens therapeutic vaccines, being immune modulators via
inducing antiviral T cell responses, will need other treatments such
as DAAs for shutting down the HCV propagation, and IFN and RBV
for their antiviral and immune modulatory activity.
2.2. TLR ligands and blocking of PD-1
The ﬁrst line of defense against invading pathogens (bacteria,
viruses, fungi, parasites) is the innate immune system. So-called
pattern recognition receptors (PRRs) that recognize pathogen asso-
ciated molecular patterns (PAMPs) are an important component of
the innate immune system (Matzinger, 2002). The most prominent
members of the PRRs are the Toll-like receptors (TLRs), which can
be divided into two groups with regard to their expression (Kawai
es within HCV. Resistance mutations occurring within known human CTL epitopes
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nd Akira, 2011). TLR3, -7, -8 and -9 are located on endosomes and
etect nucleic acids like single- (TLR7, -8) and double-stranded RNA
TLR3) and CpG-containing DNA (TLR9), while TLR1, -2, -4, -5 and -6
re expressed on the cell surface where they recognize mainly cell
all components from bacteria and fungi (Kawai and Akira, 2011).
The TLRs are composed of an ectodomain that binds the
AMP and a cytoplasmic TIR domain responsible for downstream
ignalling (Kawai and Akira, 2011). Binding of the respective ligand
eads to receptor dimerization and recruitment of a cascade of adap-
or proteins like myeloid differentiation primary-response protein
8 (MyD88), TIR domain-containing adaptor protein (TIRAP), TIR
omain-containing adaptor protein inducing IFN- (TRIF) and TRIF-
elated adaptor molecule (TRAM). MyD88 is used by almost all TLRs
xcept TLR3, which induces IFN- via TRIF and the IFN-regulated
actor 3 (IRF3). The MyD88-dependent pathway leads to the release
f nuclear factor -B (NF-B) from its inhibitor using a cascade
f signalling molecules. NF-B translocates into the nucleus and
nduces expression of inﬂammatory cytokines e.g. IL-6, IL-10, IL-12
nd TNF- (Kawai and Akira, 2011).
In HCV infection the viral RNA is recognized by retinoic acid
nducible gene I (RIG-I) and TLR3, which leads to the activation of
RF3 and NF-B, mediating an antiviral state (Seth et al., 2005). In
rder to establish a chronic infection, HCV interferes directly with
hese defense mechanisms of the innate immune system (Gale and
oy, 2005). The HCV NS3/4A encodes a serine protease that cleaves
RIF and CARDIF, disrupting the signalling cascade downstream of
LR3 and RIG-I (Li et al., 2005; Meylan et al., 2005). Finally, a recent
tudy tested the effect of blocking PD-1 in paients with chronic HCV
ith a limited effect (Gardiner et al., 2013).
Due to the signiﬁcance of TLRs for the innate immune response
owards viruses, the use of TLR ligands to stimulate/enhance the
nti-viral response is an interesting approach.
.3. Neutralizing antibodies
An obvious way to modulate the host response is to increase
he levels of neutralizing antibodies (NAbs). This can be achieved
ither by the addition of exogenous neutralizing antibodies, such as
 cocktail of HCV envelope (E) 1 and/or E2-speciﬁc NAbs. An alter-
ative way is to induce these trough vaccination, as has been done
n both chimpanzees and in humans with some success. It is fully
onceivable that an increase in Nabs may  improve on the effect of
AAs by simply blocking the ability of the remaining virus to infect
ew cells. However, limitations are that the HCV E1/2 proteins are
hose with the highest genetic variability and that HCV may  spread
irectly from cell-to-cell and not being accessible to NAbs.
.4. T cell therapy
Virus-speciﬁc CTLs have a key role in the elimination of virus-
nfected cells and this includes HCV. However due to the potency to
nduce chronicity of the HCV, patients infected with HCV ultimately
emonstrate a substantial loss of T cell function as a result of T cell
xhaustion. The loss of the ability to recognize HCV viral peptides
s ﬁrst shown as lack of interleukin (IL)-2 production, proliferative
apacity, and ex vivo killing, which is followed by an impaired abil-
ty to secrete IFN- at a ﬁnal stage of CD8+ T cell exhaustion (Kim
nd Ahmed, 2010; Klenerman and Thimme, 2012). T cell exhaustion
ay ultimately end with subsequent deletion of antigen-speciﬁc
 cells, thus prevents optimal control of chronic HCV infections
Wherry, 2011). Given that CD8+ T cells are key immunologic play-
rs in HCV infection but ultimately fail in its ability to eradication
he virus, a new “T cell redirection” approach has recently been
roposed to produce functional HCV-speciﬁc effector T cells, that
an be regarded as a passive therapeutic vaccination. This approach
elies on T cell receptor (TCR) transfer, by which the antigenUpdates 16 (2013) 60– 67
speciﬁcity can be transferred from one T cell to another by gene
transfer. TCR transfer is a cornerstone that has led to generation of
a number of TCR transgenic and retrogenic animal models (Bettini
et al., 2012; Chen et al., 2001, 2005). Lately it has opened up new
possibilities to treat tumour patients (Restifo et al., 2012).
In the case of HCV, cloned  TCR from CD8+ T cells with
speciﬁcity to NS3 (Callender el al., 2006) as well as NS5 (Pasetto
et al., 2012a) have been identiﬁed and transferred recently into
new T cells from HCV-negative human individuals. The new CD4+
and CD8+ T cells from HCV-negative individuals confer anti-
HCV reactivity and recognized HCV peptide-loaded target cells
and HCV-positive hepatocellular carcinoma cells. To date, TCRs
with speciﬁcity to the NS3 1073–1081, NS3 1406–1415 or NS5A
1992–2000 have been successfully identiﬁed and restored on new
human T cells. The HCV NS3 TCR transfer may  redirect T cells
from healthy as well as chronic HCV patients (Callender et al.,
2006; Pasetto et al., 2012b; Zhang et al., 2010) to recognize HCV
target cells with a polyfunctional response (production of IFN-,
TNF-, IL-2 and CD107a expression). Moreover, the NS3 1073 and
NS5A 1992–2000 TCR-redirected T cells demonstrated an effective
elimination of HCV replication in HLA-A2+ Huh-7 hepatocellular
carcinoma cells (HCV-replicon cells) that persistently replicat-
ing a subgenomic HCV RNA (Pasetto et al., 2012a). Interestingly,
whilst the NS3 1073 TCR resembles a high avidity TCR – capa-
ble of instructing T cells to become polyfunctional effector cells
to kill HCV+ hepatocytes in a cytolytic and HLA-A2-restricted man-
ner; the NS5A 1992 TCR instead shows features that resembles a
low/medium avidity TCR. It was  found that redirected T cells by
each of the TCR exert an effective antiviral effect on HCV repli-
con cells, however the elimination of HCV RNA+ cells appears to
occur in a non-cytolytic fashion after incubation with the NS5A
1992 TCR-redirected T cells (Fig. 4). Unlike the NS3 1073 TCR (gives
rise to high avidity, polyfunctional, cytolytic CTL) identiﬁed and
provided with the same approach, the low/medium avidity NS5A
1992 TCR appears to give rise to mostly non-cytolytic CTLs dominat-
ing by IFN- or TNF- producing cells. Although high avidity TCRs
like NS3 1073 may  be more effective in eliminating HCV+ target
cells, there is beneﬁts with non-cytolytic T cells generated with for
instance the NS5A 1992, as it may  spare the host from unwanted
tissue damage by having less hepatoxic potentials (Pasetto et al.,
2012a). Adding NS5A T cells might be an advantage when reconsti-
tuting a multi-speciﬁc antiviral T cell response in vivo to avoid the
potential overkilling of hepatocytes, however the ultimate answer
to which of the T cells are more beneﬁcial remained to be evaluated
in vivo. The new HCV TCR-redirected T cells represent some new
tools for immunological studies of HCV and may have some clini-
cal potential to help HCV patient groups that are prone to failure
of standard therapy. They may  also serve in new therapeutic com-
binations with for instance antiviral drugs to meet the potential
challenges from resistant virus strains (Fig. 4).
3. Immune modulation in the clinic
3.1. Vaccines
An increasing number of therapeutic vaccine trials have been
performed although none have so far provided any cure for HCV. On
the other hand the performed trials have shown some success, such
as reducing the viral load, activated HCV-speciﬁc T cell responses,
and last but not least, proven to be safe, tolerable and associated
with less adverse events compared to SOC therapy with peg-IFN
plus RBV+/− a ﬁrst generation PI. An interesting approach being
tested in a larger number of therapeutic vaccine trials is the com-
bination of vaccine with pegylated IFN and RBV. A brief account of
the performed and ongoing therapeutic vaccine trails are described
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Fig. 4. T cell receptor-redirected T cells can eliminate HCV RNA+ hepatocytes. The avidity of the chosen TCR (low or high) may  also determine the fate of the target hepatocyte,
as  it may  guide the CTL function towards the cytolytic or the non-cytolytic mechanisms.
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elow. Intercell AG (Vienna, Austria) has evaluated a peptide-based
accine (IC41) alone or with an adjuvant (poly-l-arginine) in phase
I clinical trials (Firbas et al., 2006; Klade et al., 2008; Wedemeyer
t al., 2009). In general this vaccine composition was safe and tol-
rable, but induced only modest decrease in viral load, and no
igniﬁcant correlation between HCV viral load decline and acti-
ation of HCV-speciﬁc T cell responses was seen. Moreover, IC41
mmunization as an add-on to pegylated IFN and RBV treatment
n chronic HCV patients did not improve cure rates (Wedemeyer
t al., 2009). Another approach utilized by Transgene S.A. (Illkirch-
raffenstaden, France), is an attenuated non-replicative vaccinia
irus Ankara (MVA) strain as a vector for delivery of HCV genes to
he infected host. In clinical phase I and II trials the TG4040 vaccine
emonstrated a good safety proﬁle, induction of IFN- producing
 cell responses, and when given in combination with pegylated
nterferon and ribavirin an early rapid virological response wasHCV-speciﬁc T cell response with DAA-based therapy.
seen in HCV infected patients (Habersetzer et al., 2011; Wedemeyer
et al., 2011, 2012b). In the same line, Okairos (Rome, Italy) have
generated Adenovirus vectors based on rare serotypes, utilizing
a prime-boost approach where human adenovirus 6 (Ad6) and
chimpanzee adenovirus 3 (ChAd3) are expressing HCV genes. The
vaccine composition primed potent T cell responses in healthy
volunteers. The immune response targeted several HCV antigens
and were still detectable one year after last vaccination (Barnes
et al., 2012). This vaccine still needs to show proof of antiviral
activity in chronic HCV infected individuals or protective immu-
nity as a preventive HCV vaccine. Others have utilized plasmid
DNA vaccines for treatment of chronic HCV infections. Chron-
Tech Pharma AB (Huddinge, Sweden) has developed a DNA-based
vaccine (ChronVac-C) delivered in combination with in vivo elec-
troporation. Results from a phase I/IIa clinical trial showed that the
ChronVac-C vaccine was  safe and tolerable, induced HCV-speciﬁc T
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ell responses and transiently reduced the viral load (Sallberg et al.,
009; Weiland et al., 2013). Interestingly, patients ﬁrst given the
NA vaccine, who thereafter started pegylated IFN and RBV treat-
ent had an improved cure rate (Weiland et al., 2013). Similarly,
lobeImmune (Louisville, Colorado) has developed a yeast cell,
nactivated Saccharomyces cerevisiae, expressing recombinant HCV
ntigens (GI-5005). The GI-5005 vaccine had a tolerable proﬁle, and
iven together with pegylated IFN and RBV it resulted in an early
irological response (Habersetzer et al., 2009). In summary, several
herapeutic vaccines have shown promising results in phase I and II
linical trials although so far none of them could cure HCV infection.
.2. TLR agonists
TLR agonists have been considered for treatment of HCV due to
heir potent effect on inducing a local IFN response. So far only a
ew have been evaluated in the clinic. A disadvantage is that the
ffect often is systemic with an immune activation also outside the
iver. The following section will summarize the current experience.
The TLR7/8 ligand Resiquimod showed little effect in combina-
ion with severe side effects at a dose of 0.01–0.02 mg/kg in two
linical phase IIa studies with an oral administration twice weekly
or four weeks (Pockros et al., 2007). The treatment seemed to
nduce IFN from pDCs via TLR7 with immediate, but transient,
ecreases in HCV RNA levels (Pockros et al., 2007).
The TLR7 agonist isatoribine has been found to transiently
educe HCV RNA levels in plasma (Horsmans et al., 2005). Also a
rodrug of isatoribine termed ANA975 was converted to isatoribine
n humans (Xiang et al., 2007). Several TLR7 agonists are currently
n clinical testing, for example GS-9620, but not data has yet been
resented.
The TLR9 agonist CPG10101 has been tested in HCV infected
atients administered subcutaneously twice weekly for four weeks.
his study showed that CPG10101 induced an immune activa-
ion with transient effects on HCV replication (McHutchison et al.,
007).
The TLR9 agonist IMO-2125 has been tested in HCV infected null
esponders and did show transient decreases in HCV RNA levels of
p to 3.5log 10 (McHutchison. Oral presentation at EASL 2010).
Overall, the TLR agonists have shown promising transient effects
n HCV infected patients and may  well be evaluated in combination
ith the IFN free DAA combinations.
. Combination of DAAs/antivirals and immune
odulation in the clinic
.1. Vaccines, antibodies and TLR agonists with IFN/RBV
The strongest evidence that immune modulation is a key com-
onent of DAA-based therapies is the difﬁculty to remove ribavirin
rom the treatment regimen with retained treatment results. This
s particularly true for patients infected by gt1a. Thus, the host
mmune response seems to be essential for elimination of HCV in
he forthcoming era of highly active DAA-based therapies.
Having acknowledged that the host immune response is needed
or a treatment to be effective a question arises – which way is the
est way and most attractive to achieve modulation of the host
esponse? The most well proven immune modulator is of IFN.
owever, a major disadvantage with IFN treatment, however, are
he many and often severe side effects. This is a major reason for
liminating IFN from the treatment of HCV infected individuals.Concerning therapeutic vaccines and their utilization in combi-
ation with HCV antiviral drugs, the only treatment reported so far
s such a combination with IFN/RBV. In this setting at least three
ifferent vaccines have been tested, a DNA vaccine delivered byUpdates 16 (2013) 60– 67
in vivo electroporation (Sallberg et al., 2009; Weiland et al., 2013),
a modiﬁed vaccinia virus Ankara strain (MVA) (Wedemeyer et al.,
2012b), and yeast cells carrying HCV proteins (Habersetzer et al.,
2009). These studies have all supported that the addition of thera-
peutic vaccination can improve either the early viral kinetics and/or
the sustained viral response. Hence, they all support the concept of
adding a therapeutic vaccination to the IFN therapy. Still lacking,
however, are studies including such a combination with DAAs. A
ﬁrst ongoing controlled study in 32 patients will test treatment
with, or without, DNA-based vaccination followed by 12 weeks of
IFN/RBV treatment. After this a ﬁrst generation protease inhibitor
will be added for the patients who  has not achieved a more than 2
log drop in HCV RNA levels week 12 (Weiland et al., personal com-
munication). This study will tell us whether the combination of a
therapeutic vaccine, IFN/RBV and a DAA can be utilized and over-
come treatment failures in difﬁcult to treat patients with chronic
HCV infection.
5. Concluding remarks
5.1. Is there a role for immune modulation in future HCV therapy?
Considering the potentially high effectivity of the coming DAAs
in cutting down the HCV replication, is there still a need for immune
modulating compounds? There is obviously no clear cut answer
to this question, but the following factors should be considered.
In real-life therapeutic situations outside clinical trials, treatment
results are in often much less effective. In particular when consid-
ering three to six months of oral therapies where the patients
must take a dosing twice or thrice per day, the regimens are
totally dependent on patient compliance. With this background
an immune therapy administered on a bi-weekly to monthly basis
that will help boost an immune response and an endogenous con-
trol of the infection might be very helpful. With the new DAAs
which effectively suppress the viral replication, the HCV induced
“immune blockade” of the host response both directly and indi-
rectly by the mere presence of HCV antigens in the circulation can
be broken. Subsequently the endogenous T cell response can be
effectively activated with an immune modulating therapy such as
a therapeutic vaccination. With this help the host activated immune
response can eliminate the remaining infected hepatocytes and
ﬁnally achieve clearance of the chronic HCV infection (Fig. 5).
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